https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:8215 Sat 24 Mar 2018 08:36:21 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7654 Sat 24 Mar 2018 08:35:59 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:2835 Sat 24 Mar 2018 08:29:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:2260 US $382; odds ratio [OR], 3.5; 95% confidence interval [CI], 2.6-4.7) and support for attending international conferences (OR, 5.4; 95% CI, 3.9-7.4). The strongest associations were seen for acting as a paid consultant to industry (OR, 9.0; 95% CI, 3.9-20.4) and for membership on advisory boards (OR, 6.9; 95% CI, 5.1-9.6). There was a strong relationship between research collaboration and accumulation of industry ties. For 1 additional tie the OR was 2.2 (95% CI, 1.2-3.8) and rose to 6.3 (95% CI, 3.5-11.1) with 3 ties and 41.8 (95% CI, 14.5-143.4) with 6 or more ties. Conclusions: Medical specialists who have research relationships with the pharmaceutical industry are much more likely to have multiple additional ties than those who do not have research relationships. Institutional review should discourage clinical researchers from developing multiple ties.]]> Sat 24 Mar 2018 08:27:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:4462 Sat 24 Mar 2018 07:18:29 AEDT ]]>